• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

艾沙康唑及对照药物对来自美国、欧洲和亚太地区同期毛霉目分离株的抗真菌活性

Antifungal Activity of Isavuconazole and Comparator Agents against Contemporaneous Mucorales Isolates from USA, Europe, and Asia-Pacific.

作者信息

Carvalhaes Cecilia G, Rhomberg Paul R, Huband Michael D, Pfaller Michael A, Castanheira Mariana

机构信息

JMI Laboratories, 345 Beaver Kreek Centre, North Liberty, IA 52317, USA.

出版信息

J Fungi (Basel). 2023 Feb 11;9(2):241. doi: 10.3390/jof9020241.

DOI:10.3390/jof9020241
PMID:36836355
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9960003/
Abstract

Isavuconazole is the only US FDA-approved antifungal for treating invasive mucormycosis. We evaluated isavuconazole activity against a global collection of Mucorales isolates. Fifty-two isolates were collected during 2017-2020 from hospitals located in the USA, Europe, and the Asia-Pacific. Isolates were identified by MALDI-TOF MS and/or DNA sequencing and susceptibility tested by the broth microdilution method following CLSI guidelines. Isavuconazole (MIC, 2/>8 mg/L) inhibited 59.6% and 71.2% of all Mucorales isolates at ≤2 mg/L and ≤4 mg/L, respectively. Among comparators, amphotericin B (MIC, 0.5/1 mg/L) displayed the highest activity, followed by posaconazole (MIC, 0.5/8 mg/L). Voriconazole (MIC, >8/>8 mg/L) and the echinocandins (MIC, >4/>4 mg/L) had limited activity against Mucorales isolates. Isavuconazole activity varied by species and this agent inhibited at ≤4 mg/L 85.2%, 72.7%, and 25% of spp. ( = 27; MIC, 1/>8 mg/L), spp. ( = 11; MIC, 4/8 mg/L), and spp. ( = 8; MIC, >8 mg/L) isolates, respectively. Posaconazole MIC values against , , and species were 0.5/8 mg/L, 0.5/1 mg/L, and 2/- mg/L, respectively; amphotericin B MIC values were 1/1 mg/L, 0.5/1 mg/L, and 0.5/- mg/L, respectively. As susceptibility profiles varied among Mucorales genera, species identification and antifungal susceptibility testing are advised whenever possible to manage and monitor mucormycosis.

摘要

艾沙康唑是美国食品药品监督管理局(FDA)批准的唯一用于治疗侵袭性毛霉病的抗真菌药物。我们评估了艾沙康唑对全球收集的毛霉目分离株的活性。2017年至2020年期间,从美国、欧洲和亚太地区的医院收集了52株分离株。通过基质辅助激光解吸电离飞行时间质谱(MALDI-TOF MS)和/或DNA测序鉴定分离株,并按照美国临床和实验室标准协会(CLSI)指南采用肉汤微量稀释法进行药敏试验。艾沙康唑(MIC,2/>8 mg/L)在≤2 mg/L和≤4 mg/L时分别抑制了59.6%和71.2%的所有毛霉目分离株。在比较的药物中,两性霉素B(MIC,0.5/1 mg/L)活性最高,其次是泊沙康唑(MIC,0.5/8 mg/L)。伏立康唑(MIC,>8/>8 mg/L)和棘白菌素类药物(MIC,>4/>4 mg/L)对毛霉目分离株的活性有限。艾沙康唑的活性因菌种而异,该药物在≤4 mg/L时分别抑制了85.2%、72.7%和25%的根霉属(n = 27;MIC,1/>8 mg/L)、毛霉属(n = 11;MIC,4/8 mg/L)和犁头霉属(n = 8;MIC,>8 mg/L)分离株。泊沙康唑对根霉属、毛霉属和犁头霉属菌种的MIC值分别为0.5/8 mg/L、0.5/1 mg/L和2/- mg/L;两性霉素B的MIC值分别为1/1 mg/L、0.5/1 mg/L和0.5/- mg/L。由于毛霉目各属之间的药敏谱不同,建议尽可能进行菌种鉴定和抗真菌药敏试验,以管理和监测毛霉病。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4006/9960003/54fde493d273/jof-09-00241-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4006/9960003/54fde493d273/jof-09-00241-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4006/9960003/54fde493d273/jof-09-00241-g001.jpg

相似文献

1
Antifungal Activity of Isavuconazole and Comparator Agents against Contemporaneous Mucorales Isolates from USA, Europe, and Asia-Pacific.艾沙康唑及对照药物对来自美国、欧洲和亚太地区同期毛霉目分离株的抗真菌活性
J Fungi (Basel). 2023 Feb 11;9(2):241. doi: 10.3390/jof9020241.
2
In Vitro Activity of Isavuconazole and Comparators against Clinical Isolates of the Mucorales Order.艾沙康唑及对照药物对毛霉目临床分离株的体外活性
Antimicrob Agents Chemother. 2015 Dec;59(12):7735-42. doi: 10.1128/AAC.01919-15. Epub 2015 Oct 5.
3
A Revised Species Concept for Opportunistic Species Reveals Species-Specific Antifungal Susceptibility Profiles.机会性致病物种的修订物种概念揭示了特定物种的抗真菌药敏谱。
Antimicrob Agents Chemother. 2019 Jul 25;63(8). doi: 10.1128/AAC.00653-19. Print 2019 Aug.
4
In Vitro Antifungal Drug Resistance Profiles of Clinically Relevant Members of the Mucorales (Mucoromycota) Especially with the Newer Triazoles.毛霉目(毛霉亚门)临床相关成员的体外抗真菌药物耐药谱,尤其针对新型三唑类药物。
J Fungi (Basel). 2021 Apr 2;7(4):271. doi: 10.3390/jof7040271.
5
Epidemiology and Antifungal Susceptibilities of Mucoralean Fungi in Clinical Samples from the United States.美国临床样本中毛霉目真菌的流行病学和抗真菌药敏性。
J Clin Microbiol. 2021 Aug 18;59(9):e0123021. doi: 10.1128/JCM.01230-21.
6
Comparative activity of posaconazole and systemic azole agents against clinical isolates of filamentous fungi from a global surveillance programme.泊沙康唑与全身用唑类药物对全球监测项目中丝状真菌临床分离株的比较活性
JAC Antimicrob Resist. 2021 Jun 26;3(2):dlab088. doi: 10.1093/jacamr/dlab088. eCollection 2021 Jun.
7
In vitro Activity of Isavuconazole and Comparators Against Clinical Isolates of Molds from a Multicenter Study in China.在中国一项多中心研究中,艾沙康唑及对照药物对临床分离霉菌的体外活性
Infect Drug Resist. 2022 Apr 22;15:2101-2113. doi: 10.2147/IDR.S360191. eCollection 2022.
8
Isavuconazole: A new broad-spectrum azole. Part 1: In vitro activity.伊曲康唑:一种新型广谱唑类药物。第 1 部分:体外活性。
J Mycol Med. 2018 Mar;28(1):8-14. doi: 10.1016/j.mycmed.2018.02.005. Epub 2018 Mar 11.
9
Activity of Isavuconazole against Opportunistic Fungal Pathogens from Two Mycology Reference Laboratories.伊曲康唑对两个真菌学参考实验室的机会性真菌病原体的活性。
Antimicrob Agents Chemother. 2018 Sep 24;62(10). doi: 10.1128/AAC.01230-18. Print 2018 Oct.
10
Evaluation of Rezafungin Provisional CLSI Clinical Breakpoints and Epidemiological Cutoff Values Tested against a Worldwide Collection of Contemporaneous Invasive Fungal Isolates (2019 to 2020).评估 Rezafungin 的 CLSI 临时临床折点和流行病学 cutoff 值,该值针对来自全球范围的同期侵袭性真菌分离株进行了测试(2019 年至 2020 年)。
J Clin Microbiol. 2022 Apr 20;60(4):e0244921. doi: 10.1128/jcm.02449-21. Epub 2022 Mar 7.

引用本文的文献

1
Mucormycosis.毛霉病
Infect Dis Clin North Am. 2025 Mar;39(1):121-144. doi: 10.1016/j.idc.2024.11.008. Epub 2024 Dec 4.
2
Changes in fungal taxonomy: mycological rationale and clinical implications.真菌分类学的变化: mycological 原理和临床意义。
Clin Microbiol Rev. 2023 Dec 20;36(4):e0009922. doi: 10.1128/cmr.00099-22. Epub 2023 Nov 6.
3
Virulence traits and novel drug delivery strategies for mucormycosis post-COVID-19: a comprehensive review.新冠病毒大流行后毛霉病的毒力特征和新型药物输送策略:全面综述。

本文引用的文献

1
A Multiplex PCR and DNA-Sequencing Workflow on Serum for the Diagnosis and Species Identification for Invasive Aspergillosis and Mucormycosis.用于侵袭性曲霉病和毛霉病诊断和种属鉴定的血清多重 PCR 和 DNA 测序工作流程。
J Clin Microbiol. 2023 Jan 26;61(1):e0140922. doi: 10.1128/jcm.01409-22. Epub 2022 Dec 19.
2
Invasive Respiratory Fungal Infections in COVID-19 Critically Ill Patients.新型冠状病毒肺炎危重症患者的侵袭性呼吸道真菌感染
J Fungi (Basel). 2022 Apr 17;8(4):415. doi: 10.3390/jof8040415.
3
COVID-19 Associated Rhino-Orbital-Cerebral Mucormycosis: A Proposed Classification and Treatment Strategies.
Front Immunol. 2023 Sep 25;14:1264502. doi: 10.3389/fimmu.2023.1264502. eCollection 2023.
4
Epidemiology, Modern Diagnostics, and the Management of Mucorales Infections.毛霉目感染的流行病学、现代诊断方法及管理
J Fungi (Basel). 2023 Jun 12;9(6):659. doi: 10.3390/jof9060659.
5
A Case of Primary Multifocal Cutaneous Mucormycosis in a Pediatric Patient with Newly Diagnosed Acute Lymphoblastic Leukemia.儿童新发急性淋巴细胞白血病合并原发性多灶性皮肤毛霉菌病 1 例
Medicina (Kaunas). 2023 May 9;59(5):905. doi: 10.3390/medicina59050905.
新型冠状病毒肺炎相关鼻眶脑毛霉菌病:一种拟议的分类及治疗策略
Infect Disord Drug Targets. 2022;22(8):1-7. doi: 10.2174/1871526522666220408110135.
4
Evaluation of Serum Mucorales Polymerase Chain Reaction (PCR) for the Diagnosis of Mucormycoses: The MODIMUCOR Prospective Trial.血清接合菌聚合酶链反应(PCR)在毛霉病诊断中的评估:MODIMUCOR 前瞻性试验。
Clin Infect Dis. 2022 Sep 14;75(5):777-785. doi: 10.1093/cid/ciab1066.
5
Consensus guidelines for the diagnosis and management of invasive fungal disease due to moulds other than Aspergillus in the haematology/oncology setting, 2021.2021年血液学/肿瘤学环境中曲霉菌以外霉菌所致侵袭性真菌病的诊断和管理共识指南
Intern Med J. 2021 Nov;51 Suppl 7:177-219. doi: 10.1111/imj.15592.
6
COVID-19 and mucormycosis superinfection: the perfect storm.COVID-19 与毛霉菌感染:完美风暴。
Infection. 2021 Oct;49(5):833-853. doi: 10.1007/s15010-021-01670-1. Epub 2021 Jul 24.
7
ECMM/ISHAM recommendations for clinical management of COVID-19 associated mucormycosis in low- and middle-income countries.ECMM/ISHAM 关于中低收入国家 COVID-19 相关毛霉菌病临床管理的建议。
Mycoses. 2021 Sep;64(9):1028-1037. doi: 10.1111/myc.13335. Epub 2021 Jul 26.
8
Multicenter Epidemiologic Study of Coronavirus Disease-Associated Mucormycosis, India.印度冠状病毒疾病相关毛霉菌病的多中心流行病学研究。
Emerg Infect Dis. 2021 Sep;27(9):2349-2359. doi: 10.3201/eid2709.210934. Epub 2021 Jun 4.
9
In Vitro Antifungal Drug Resistance Profiles of Clinically Relevant Members of the Mucorales (Mucoromycota) Especially with the Newer Triazoles.毛霉目(毛霉亚门)临床相关成员的体外抗真菌药物耐药谱,尤其针对新型三唑类药物。
J Fungi (Basel). 2021 Apr 2;7(4):271. doi: 10.3390/jof7040271.
10
Breakthrough invasive fungal infection after liver transplantation in patients on targeted antifungal prophylaxis: A prospective multicentre study.肝移植术后靶向抗真菌预防患者发生突破性侵袭性真菌感染:一项前瞻性多中心研究。
Transpl Infect Dis. 2021 Aug;23(4):e13608. doi: 10.1111/tid.13608. Epub 2021 May 3.